Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
Authors
Keywords
-
Journal
LANCET INFECTIOUS DISEASES
Volume 21, Issue 4, Pages 493-506
Publisher
Elsevier BV
Online
2020-11-19
DOI
10.1016/s1473-3099(20)30476-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Control of Ebola virus disease outbreaks: comparison of health care worker-targeted and community vaccination strategies
- (2019) Alexis Robert et al. Epidemics
- Ebola virus disease
- (2019) Denis Malvy et al. LANCET
- Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania
- (2019) Zacchaeus Anywaine et al. JOURNAL OF INFECTIOUS DISEASES
- Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Nairobi, Kenya
- (2019) Gaudensia Mutua et al. JOURNAL OF INFECTIOUS DISEASES
- Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults
- (2019) Scott A Halperin et al. JOURNAL OF INFECTIOUS DISEASES
- Dynamics of the humoral immune response to a prime-boost Ebola vaccine: quantification and sources of variation
- (2019) Chloé Pasin et al. JOURNAL OF VIROLOGY
- Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination
- (2018) Lise Gross et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay
- (2018) James Logue et al. JOURNAL OF VIROLOGICAL METHODS
- OUP accepted manuscript
- (2018) TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
- Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara–Vectored Ebola Vaccines at 1 Year
- (2017) Rebecca L. Winslow et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)
- (2017) Ana Maria Henao-Restrepo et al. LANCET
- Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Feng-Cai Zhu et al. LANCET
- Chimpanzee Adenovirus Vector Ebola Vaccine
- (2017) Julie E. Ledgerwood et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
- (2017) Jason A. Regules et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines
- (2016) Iain D. Milligan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA
- (2016) Katie Ewer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
- (2015) Feng-Cai Zhu et al. LANCET
- Ebola virus disease in the Democratic Republic of the Congo, 1976-2014
- (2015) Alicia Rosello et al. eLife
- Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge
- (2014) Daphne A Stanley et al. NATURE MEDICINE
- Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates
- (2013) A. Marzi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates
- (2012) G. Wong et al. Science Translational Medicine
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started